SCHEMBL6504180

SCHEMBL6504180

CCc1ccccc1Oc1cccc(CN2CCC(n3c(=O)[nH]c4ccccc43)CC2)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 15/20 0.76
OPRL1 P41146 3/20 0.64
OPRK1 P41145 3/20 0.64
OPRD1 P41143 2/20 0.57
DRD2 P14416 5/20 0.56
CHRM1 P11229 3/20 0.56
CHRM2 P08172 2/20 0.56
ADRA1D P25100 2/20 0.56
ADRA1A P35348 2/20 0.56
ADRA1B P35368 2/20 0.56
CHRM4 P08173 1/20 0.56
CHRM5 P08912 1/20 0.56
CHRM3 P20309 1/20 0.56
HTR2C P28335 1/20 0.56
DRD4 P21917 3/20 0.55
DRD3 P35462 2/20 0.55
CACNA1F O60840 1/20 0.55
DRD1 P21728 1/20 0.55
HTR7 P34969 1/20 0.55
CACNA1D Q01668 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7068005 0.90 OPRM1 (0.84) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL7067624 0.88 OPRM1 (0.74) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6498522 0.88 OPRM1 (0.74) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6496007 0.87 OPRM1 (0.83) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6498307 0.87 OPRM1 (0.73) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6498769 0.87 OPRM1 (0.73) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6499659 0.87 OPRM1 (0.73) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6503296 0.87 OPRM1 (0.73) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6497509 0.87 OPRM1 (0.82) OPRM1OPRL1OPRK1OPRD1DRD2
SCHEMBL6507053 0.86 OPRM1 (0.72) OPRM1OPRL1OPRK1OPRD1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2005-06-30 US disclosed
WO-2005000818-A1 5-SUBSTITUTED-4-`(SUBSTITUTED PHENYL)!AMINO!-2-PYRIDONE DEVIATIVES FOR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor CCR8, CCL11, CCR5 OPRM1 494/4885OPRL1 140/4885OPRK1 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.